

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome
Direttore/Responsabile

Telefono
E-mail istituzionale

BRONTE VINCENZO

Direttore dell'UO di Immunologia, Dipartimento di Patologia e Diagnostica AOUIVR e Professore Ordinario di Immunologia e Direttore della Sezione di Immunologia del Dipartimento universitario di Medicina, Università degli Studi di Verona

045 8124007

vincenzo.bronte @aovr.veneto.it; vincenzo.bronte@univr.it

ESPERIENZA LAVORATIVA

• Date (da – a)

- Da giugno 2025 ad oggi: Direttore UO di Immunologia, Dipartimento di Patologia e Diagnostica AOUIVR e Professore Ordinario di Immunologia e Direttore della Sezione di Immunologia del Dipartimento Universitario di Medicina, Università degli Studi di Verona;
- Da marzo 2022 a maggio 2025: Direttore Scientifico presso l'Istituto Oncologico Veneto di Padova, Italia
- Da gennaio 2011 a febbraio 2022: Professore Ordinario di Immunologia e Direttore della Sezione di Immunologia afferente al Dipartimento di Patologia e Diagnostica (congedo temporaneo richiesto per la nomina di Direttore Scientifico)
- 2007-2014: Capo gruppo presso l'Istituto Veneto di Medicina Molecolare (VIMM), Padova, Italia.
- 1997-2010: Direttore del Laboratorio di tipizzazione HLA e dell'Unità di Oncogenomica presso l'Istituto Oncologico Veneto di Padova, Italia.
- 1992-2010: Dirigente Medico presso l'Istituto Oncologico Veneto (IRCCS) Padova, Italia; Professore a contratto di Immunologia e Patologia presso la Facoltà di Medicina dell'Università degli Studi di Padova, Italia.
- Febbraio 1994 - Settembre 1996: esperienza come "exchange scientist" al Surgery Branch del National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
- 1990 - 1992: Borsa Post-dottorato finanziata dall'Associazione Italiana per la Ricerca sul Cancro (AIRC).
- 1988 - 1989: Borsa di studio finanziata da Fidia Pharmaceuticals – progetto di ricerca sviluppato presso l'Istituto di Oncologia dell'Università degli Studi di Padova, Italia.
- Novembre - Dicembre, 1989: visiting fellow presso i laboratori Roche, Basilea, Svizzera.

• Nome e indirizzo del datore di lavoro

• Tipo di azienda o settore
• Tipo di impiego

Azienda Ospedaliera Universitaria Integrata (AOUI), Piazzale Stefani 1 - 37126 Verona
Università degli Studi di Verona, via Dell'artigliere 8 - 37129 Verona

Azienda Ospedaliera Universitaria Integrata e Università degli Studi di Verona

Dirigente medico di secondo livello per Azienda Ospedaliera Universitaria Integrata di Verona.
Professore Ordinario in Immunologia, Facoltà di Medicina e Chirurgia per Università di Verona.

• Principali mansioni e responsabilità

Direttore dell'UO di Immunologia: guida, supervisore, coordinatore e garante dell'UO.
Professore Ordinario di Immunologia e Direttore della Sezione di Immunologia del Dipartimento Universitario di Medicina: docente di Immunologia per il corso di Laurea in Medicina e Chirurgia, responsabile della didattica e della ricerca scientifica della sezione

ISTRUZIONE E FORMAZIONE

- Date (da – a)
 - 07/18/1988: Laurea in Medicina e Chirurgia summa Cum Laude, Università degli Studi di Padova, Italia.
 - 12/21/1992: Specializzazione (70/70) in Allergia e Immunologia, Università degli Studi di Padova, Italia.
- Nome e tipo di istituto di istruzione o formazione

Università degli Studi di Padova, Italia.
- Principali materie / abilità professionali oggetto dello studio

Allergia e Immunologia Clinica, analisi di laboratorio, immunoematologia.
- Qualifica conseguita

Laurea in Medicina e Chirurgia (110 lode), Specializzazione (70/70) in Allergia e Immunologia Clinica
- Livello nella classificazione nazionale (se pertinente)

CAPACITÀ E COMPETENZE

PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

MADRELINGUA

Italiano

ALTRE LINGUA

Inglese

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

eccellente

eccellente

eccellente

CAPACITÀ E COMPETENZE

ORGANIZZATIVE

Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.

Il Prof. Bronte coordina gruppi di ricerca e di lavoro e progetti scientifici sin dal 1992, anno in cui è ritornato in Italia come Dirigente Medico presso l'Istituto Oncologico Veneto (IRCCS) Padova, Italia, dopo un periodo di esperienza all'estero esperienza come "exchange scientist" al Surgery Branch del National Cancer Institute, National Institute of Health, Bethesda, MD, USA.

01/09/2020 - 28/02/2022: Presidente CEVS attività accreditamento iniziale Scuola Superiore Sant'Anna di Pisa, Italia.

2018 - 2022: Direttore della scuola di dottorato "Scienze della vita e della salute" presso l'Università degli Studi di Verona, Italia.

2019 a 2021: co-delegato alla Progettazione e sviluppo della ricerca presso l'Università degli Studi di Verona, Italia.

01/01/2014 - 28/02/2022: Membro del Comitato Tecnico Scientifico del Centro Interdipartimentale di Servizio alla Ricerca Sperimentale (CIRSAL) dell'Università degli Studi di Verona, Italia.

01-01-2014 - 28/02/2022: Componente del Collegio dei Docenti della Scuola di Dottorato in Scienze della Vita e della Salute, corso "Infiammazione, Immunità e Cancro", presso l'Università degli Studi di Verona, Italia.

01/01/2011 - ad oggi: Componente del Collegio Didattico del corso di Laurea in Medicina e Chirurgia presso l'Università degli Studi di Verona, Italia.

2025: Membro del Comitato Scientifico Organizzativo per AAC 2025, 10° Congresso Annuale dell'Alleanza Contro il Cancro, Nuove Tecnologie e Strategie per Combattere il Cancro. Verona, Italia, 18-20 settembre 2025.

2025: Membro del Comitato Scientifico Organizzativo Internazionale per CICON-25, CRI-ENCI, Nona Conferenza Internazionale sull' Immunoterapia del Cancro, TRANSLATING SCIENCE INTO SURVIVAL. Utrecht, Paesi Bassi, 10-12 settembre 2025.

2025: Membro del Comitato Scientifico Organizzativo Internazionale per CIMT 2025, Mainz, Germania, 11-14 maggio 2025.

2025: Membro del Comitato Scientifico Organizzativo Internazionale per ISPHAV 2025: Cancro e Malattie Cardiovascolari, Meccanismi Comuni e Strategie di Prevenzione. Erice, Italia, 27-30 luglio 2025.

2024: Membro del Comitato Esecutivo della CIMT (Associazione Tedesca per l'Immunoterapia del Cancro).

2024 ad oggi: President of Network Italiano per la BioTerapia dei Tumori (NIBIT) Scientific Society.

2018: Consigliere del consiglio direttivo del Network Italiano per la BioTerapia dei Tumori, (NIBIT).

2018: Componente del Comitato Scientifico organizzativo per il 32° congresso annuale dell' European Macrophage and Dendritic Cell Society, (EMDS) - "The cross talk between macrophages and dendritic cells: from immunometabolism to single cell fate", 27 - 29 Settembre, Verona, Italia.

2016: Membro eletto dell' European Academy for Tumor Immunology, (EATI).

2016: Membro del Comitato Scientifico Locale del 58° incontro annuale della Società Italiana di Ricerca sul Cancro, (SIC): "Revolutionary Road. Accelerating conversion of cancer biology into personalized clinical oncology", 5 - 8 Settembre, Verona, Italia.

2016: Membro del Comitato Internazionale del Society for Immunotherapy of Cancer (SITC) e organizzatore del congresso "Regulatory Myeloid Suppressor Cells Conference", 16 - 19 Giugno, Philadelphia, PA, USA.

2015: Membro del Cancer Immunotherapy Fellowships Awards e dell' Immune Biomarkers Task Force dell' International Society for Immunotherapy of Cancer, (SITC).
 2013: Membro della Commissione del Consiglio Scientifico del 15° Congresso Internazionale di Immunologia, Milano, Italia.
 2012: Consigliere del Comitato Scientifico del Corso Avanzato di Citometria a Flusso - Applicazioni in Oncologia e Immunologia, Verona, Italia.
 2009: Consiglio dei Direttori del Cancer Italian Society, (SIC).
 2008: Membro della Commissione dei Consiglieri Scientifici dell'Accademia Nazionale di Medicina.

CAPACITÀ E COMPETENZE TECNICHE

*Con computer, attrezzature specifiche,
macchinari, ecc.*

Il Prof. Vincenzo Bronte, M.D., ha iniziato la sua carriera di ricerca presso l'Università di Padova, Italia, per poi entrare nel laboratorio del Dr. Restifo presso il Surgery Branch dei National Institutes of Health (NIH) a Bethesda, MD, USA. Lì ha dato contributi significativi alla ricerca in immunologia e immunoterapia oncologica, diventando riconosciuto a livello internazionale come uno dei maggiori esperti nello sviluppo di nuove strategie immunoterapeutiche contro il cancro.

Il Prof. Bronte è stato tra i primi scienziati a identificare e caratterizzare le cellule mieloidi soppressorie (MDSC), una popolazione di cellule mieloidi con importanti funzioni immunoregatorie in grado di compromettere l'efficacia delle immunoterapie emergenti.

Dopo il periodo all'estero, il Prof. Bronte è tornato in Italia, lavorando inizialmente presso l'Università di Padova/Azienda Ospedaliera e successivamente presso l'Università di Verona/Azienda Ospedaliera Universitaria Integrata (AOUI), dove ha continuato i suoi studi innovativi nell'ambito dell'immunologia dei tumori.

Durante la sua carriera, il Prof. Bronte ha contribuito a identificare caratteristiche fondamentali dei tumori che hanno ridefinito la comprensione dell'immunologia tumorale. Le cinque pietre miliari più significative del suo lavoro sono:

1. Identificazione delle MDSC nei topi portatori di tumore e nei pazienti oncologici: il Prof. Bronte ha svolto un ruolo fondamentale nell'elucidare la biologia delle MDSC nei modelli murini tumorali, dimostrando il loro ruolo nel limitare l'immunità antitumorale (Blood, 2000; Journal of Clinical Investigation, 2006; Immunity, 2013; Immunity, 2014; Nature Communications, 2016). Ha inoltre contribuito a studi clinici che hanno esplorato le MDSC come potenziali biomarcatori del cancro (Nature Medicine, 2012).
2. Caratterizzazione dei percorsi molecolari ed enzimatici che guidano l'immunosoppressione mieloide-dipendente: il Prof. Bronte si è concentrato sul ruolo di arginasi-1 e NO sintasi inducibile nella regolazione dell'attività immunosoppressiva delle cellule mieloidi, contribuendo alla comprensione del ruolo del metabolismo dell'arginina nella progressione del cancro (Immunity, 2015; Cancer Cell, 2016; Immunity, 2017; Sci. Transl. Med, 2023).
3. Sviluppo di strumenti innovativi per superare l'immunosoppressione associata ai tumori: ha contribuito allo sviluppo di approcci terapeutici mirati a invertire l'immunosoppressione e potenziare l'immunità antitumorale, portando a significativi progressi nell'immunoterapia oncologica (Journal of Experimental Medicine, 2005; Science Translational Medicine, 2023).
4. Definizione del ruolo della mielopoiesi d'emergenza indotta dal tumore nelle metastasi: la ricerca del Prof. Bronte ha identificato come le alterazioni della mielopoiesi indotte dal cancro favoriscano la generazione di elementi pro-tumoral che facilitano la diffusione metastatica (Cancer Discovery, 2020).
5. Avanzamento di immunoterapie innovative per il cancro: il Prof. Bronte è stato fondamentale nello sviluppo di immunoterapie sia attive sia passive. Il suo lavoro comprende lo sviluppo di vaccini a DNA (Cancer Research, 2001; Cancer Research, 2008), virali (Journal of Immunology, 1995) e peptidici (Cancer Immunology Research, 2021), nanoparticelle con proprietà immunomodulanti (Journal of Immunology, 2017) e terapie adottive basate sul trasferimento di cellule T (Blood, 2010; Cancer Research, 2016).

Il Prof. Bronte è autore di circa 260 articoli pubblicati su riviste scientifiche peer-reviewed e 17 monografie e capitoli in volumi collettivi. Nel 2008, la prestigiosa rivista "Science" gli ha dedicato un articolo insieme al collega americano Dmitry Gabrilovich, riconoscendoli autori di una delle più importanti scoperte scientifiche nel campo dell'immunologia tumorale: l'identificazione delle MDSC (Marx J., Science, 2008, 319:154-6). Il suo indice H è di 87 nel database Scopus (con 35.465 citazioni), 87 in Web of Science (con 32.590 citazioni) e 94 (i10-index 191) su Google Scholar (con 48.554 citazioni). Tra le sue pubblicazioni, 23 hanno ricevuto almeno un commento e 13 sono state valutate da "Faculty of 1000". Inoltre, il Prof. Bronte è co-inventore di 10 brevetti. Negli ultimi 20 anni, ha partecipato come relatore invitato a più di 190 congressi nazionali e internazionali. Il Prof. Bronte è stato riconosciuto nel 2023 nel World Scientist and University Rankings di AD Scientific Index. È stato incluso nella seconda edizione della classifica Research.com tra i

migliori studiosi in immunologia del 2022. Inoltre, è entrato nella classifica 2021 di Stanford University come uno dei migliori scienziati a livello mondiale (top 2%). È stato inoltre inserito nella lista Highly Cited Researchers di Clarivate Analytics per gli anni 2018, 2019 e 2020, riconoscimento riservato ai ricercatori con prestazioni eccezionali, dimostrate dalla produzione di numerose pubblicazioni altamente citate che rientrano nell'1% più citato per campo e anno su Web of Science.

CAPACITÀ E COMPETENZE

FOTOGRAFIA, DISEGNO

ARTISTICHE

Musica, scrittura, disegno ecc.

PUBBLICAZIONI

1. Dusi S, Bronte V, De Sanctis F. IL-27: overlocking cytotoxic T lymphocytes to boost cancer immunotherapy. *Signal Transduct Target Ther*. 2025 Apr 21;10(1):126. doi: 10.1038/s41392-025-02212-z. PMID: 40254608; PMCID: PMC12009969.
2. Belmonte B, Spada S, Allavena P, Benelli M, Bronte V, Casorati G, D'Ambrosio L, Ferrara R, Mondino A, Nisticò P, Scommaggio R, Tazzari M, Tripodo C, Sica A, Ferrucci PF. Highlighting recent achievements to advance more effective cancer immunotherapy. *J Exp Clin Cancer Res*. 2025 Feb 18;44(1):57. doi: 10.1186/s13046-025-03316-8. PMID: 39966867; PMCID: PMC11834592.
3. Belmonte B, Spada S, Allavena P, Benelli M, Bronte V, Casorati G, D'Ambrosio L, Ferrara R, Mondino A, Nisticò P, Scommaggio R, Tazzari M, Tripodo C, Sica A, Ferrucci PF. Highlighting recent achievements to advance more effective cancer immunotherapy. *Journal of experimental & clinical cancer research*. 2025 Feb 18 ;44(1):57. doi: 10.1186/s13046-025-03316-8.
4. Musiu C, Adamo A, Caligola S, Agostini A, Frusteri C, Lupo F, Boschi F, Busato A, Poffe O, Anselmi C, Vella A, Wang T, Dusi S, Piro G, Carbone C, Tortora G, Marzola P, D'Onofrio M, Crinò SF, Corbo V, Scarpa A, Salvia R, Malleo G, Lionetto G, Sartoris S, Ugel S, Bassi C, Bronte V, Paiella S, De Sanctis F. Local ablation disrupts immune avasion in pancreatic cancer. *Cancer Lett*. 2025 Jan 28;609:217327. doi: 10.1016/j.canlet.2024.217327. Epub 2024 Nov 22.
5. Akkari L, Amit I, Bronte V, Fridlender ZG, Gabrilovich DI, Ginhoux F, Hedrick CC, Ostrand-Rosenberg S. Defining myeloid-derived suppressor cells. *Nat Rev Immunol*. 2024 Dec;24(12):850-857. doi: 10.1038/s41577-024-01062-0. Epub 2024 Jul 5.
6. Canè S, Geiger R, Bronte V. The roles of arginases and arginine in immunity. *Nat Rev Immunol*. 2024 Oct 17. doi: 10.1038/s41577-024-01098-2.
7. Lupo F, Pezzini F, Pasini D, Fiorini E, Adamo A, Veghini L, Bevere M, Frusteri C, Delfino P, D'agosto S, Andreani S, Piro G, Malinova A, Wang T, De Sanctis F, Lawlor RT, Hwang CI, Carbone C, Amelio I, Bailey P, Bronte V, Tuveson D, Scarpa A, Ugel S, Corbo V. Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. *Gut*. 2024 Jul 11;73(8):1321-1335. doi: 10.1136/gutjnl-2023-329807.
8. De Sanctis F, Dusi S, Caligola S, Anselmi C, Petrova V, Rossi B, Angelini G, Erdeljan M, Wöll S, Schlitter AM, Metzler T, Steiger K, Borok Z, Bailey P, Bauer A, Halin C, Boschi F, Giugno R, Canè S, Lawlor R, Corbo V, Scarpa A, Constantin G, Ugel S, Vascotto F, Sahin U, Türeci Ö, Bronte V. Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer. *Immunity*. 2024 Jun 11;57(6):1378-1393.e14. doi: 10.1016/j.immuni.2024.04.021. Epub 2024 May 14.
9. Caligola S, Giacobazzi L, Canè S, Vella A, Adamo A, Ugel S, Giugno R, Bronte V. GateMeClass: Gate Mining and Classification of cytometry data. *Bioinformatics*. 2024 May 2;40(5):btae322. doi: 10.1093/bioinformatics/btae322.
10. Buja A, De Luca G, Zorzi M, Bovo E, Mocellin S, Trevisiol C, Bronte V, Guzzinati S, Rugge M. Thirty-two-year trends of cancer incidence by sex and cancer site in the Veneto Region from 1987 to 2019. *Front Public Health*. 2024 Jan 8;11:1267534. doi: 10.3389/fpubh.2023.1267534. eCollection 2023.
11. Pettinella F, Lattanzi C, Donini M, Caveggon E, Marini O, Iannoto G, Costa S, Zenaro E, Fortunato TM, Gasperini S, Giani M, Belluomini L, Sposito M, Insolda J, Scaglione IM, Milella M, Adamo A, Poffe O, Bronte V, Dusi S, Cassatella MA, Ugel S, Pilotto S, Scapini P. Plasmacytoid Dendritic Cell, Slan+-Monocyte and Natural Killer Cell Counts Function as Blood Cell-Based Biomarkers for Predicting Responses to Immune Checkpoint Inhibitor Monotherapy in Non-Small Cell Lung Cancer Patients. *Cancers (Basel)*. 2023 Nov 3;15(21):5285. doi: 10.3390/cancers15215285.
12. Adamo A, Frusteri C, Pilotto S, Caligola S, Belluomini L, Poffe O, Giacobazzi L, Dusi S, Musiu C, Hu Y, Wang T, Rizzini D, Vella A, Canè S, Sartori G, Insolda J, Sposito M, Incani UC, Carbone C, Piro G, Pettinella F, Qi F, Wang D, Sartoris S, De Sanctis F, Scapini P, Dusi S, Cassatella MA, Bria E, Milella M, Bronte V, Ugel S. Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients. *Oncoimmunology*. 2023 Sep 14;12(1):2253644. doi: 10.1080/2162402X.2023.2253644. eCollection 2023.

13. Bellone M, Brevi A, Bronte V, Dusi S, Ferrucci PF, Nisticò P, Rosato A, Russo V, Sica A, Toietta G, Colombo MP. Cancer immunity and immunotherapy beyond COVID-19. *Cancer Immunol Immunother.* 2023 Jul;72(7):2541-2548. doi: 10.1007/s00262-023-03411-9. Epub 2023 Mar 30.
14. Turri G, Caligola S, Ugel S, Conti C, Zenuni S, Barresi V, Ruzzenente A, Lippi G, Scarpa A, Bronte V, Guglielmi A, Pedrazzani C. Pre-diagnostic prognostic value of leukocytes count and neutrophil-to-lymphocyte ratio in patients who develop colorectal cancer. *Front Oncol.* 2023 Jun 5;13:1148197. doi: 10.3389/fonc.2023.1148197. eCollection 2023.
15. Saleme V, Vedelago M, Sarcinella A, Moietta F, Piccolantonio A, Moiso E, Centonze G, Manco M, Guala A, Lamolinara A, Angelini C, Morellato A, Natalini D, Calogero R, Incarnato D, Oliviero S, Conti L, Iezzi M, Tosoni D, Bertalot G, Freddi S, Tucci FA, De Sanctis F, Frusteri C, Ugel S, Bronte V, Cavallo F, Provero P, Gai M, Taverna D, Turco E, Pece S, Defilippi P. p140Cap inhibits β -Catenin in the breast cancer stem cell compartment instructing a protective anti-tumor immune response. *Nat Commun.* 2023 May 11;14(1):2350. doi: 10.1038/s41467-023-37824-y.
16. Bronte V, Pittet MJ. The Spleen in Local and Systemic Regulation of Immunity. *Immunity.* 2023 May 9;56(5):1152. doi: 10.1016/j.immuni.2023.04.004.
17. Canè S, Barouni RM, Fabbi M, Cuozzo J, Fracasso G, Adamo A, Ugel S, Trovato R, De Sanctis F, Giacca M, Lawlor R, Scarpa A, Rusev B, Lionetto G, Paiella S, Salvia R, Bassi C, Mandruzzato S, Ferrini S, Bronte V. Neutralization of NET-associated human ARG1 enhances cancer immunotherapy. *Sci Transl Med.* 2023 Mar 15;15(687):eabq6221. doi: 10.1126/scitranslmed.abq6221. Epub 2023 Mar 15.
18. Raccosta L, Marinozzi M, Costantini S, Maggioni D, Ferreira LM, Corna G, Zordan P, Sorice A, Farinello D, Bianchessi S, Riba M, Lazarevic D, Provero P, Mack M, Bondanza A, Nalvarte I, Gustafsson JA, Ranzani V, De Sanctis F, Ugel S, Baron S, Lobaccaro JA, Pontini L, Pacciarini M, Traversari C, Pagani M, Bronte V, Sitia G, Antonson P, Brendolan A, Budillon A, Russo V. Harnessing the reverse cholesterol transport pathway to favor differentiation of monocyte-derived APCs and antitumor responses. *Cell Death Dis.* 2023 Feb 15;14(2):129. doi: 10.1038/s41419-023-05620-7.
19. Bellone M, Brevi A, Bronte V, Dusi S, Ferrucci PF, Nisticò P, Rosato A, Russo V, Sica A, Toietta G, Colombo MP. Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020 *Cancer Immunol Immunother.* 2022 Jul;71(7):1787-1794. doi: 10.1007/s00262-022-03145-0. Epub 2022 Jan 16.
20. Bellone M, Bregni M, Bronte V, Ugel S, Ferrucci PF, Di Nicola M, Nisticò P, Zuccolotto G, Rosato A, Russo V, Sica A, Colombo MP. Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy. *Cancer Immunol Immunother.* 2022 Jul;71(7):1777-1786. doi: 10.1007/s00262-021-03104-1. Epub 2021 Nov 9.
21. Zhang M, Wang L, Liu W, Wang T, De Sanctis F, Zhu L, Zhang G, Cheng J, Cao Q, Zhou J, Tagliabue A, Bronte V, Yan D, Wan X, Yu G. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors. *J Immunol Res.* 2022 Jun 22;2022:2253436. doi: 10.1155/2022/2253436. eCollection 2022.
22. Chilosi M, Doglioni C, Ravaglia C, Martignoni G, Salvagno GL, Pizzolo G, Bronte V, Poletti V. Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keyurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19. Pneumonia. *Biomedicines.* 2022 Jun 6;10(6):1332. doi: 10.3390/biomedicines10061332.
23. Calzetti F, Finotti G, Tamassia N, Bianchetto-Aguilera F, Castellucci M, Canè S, Lonardi S, Cavallini C, Matte A, Gasperini S, Signoretti I, Benedetti F, Bonifacio M, Vermi W, Ugel S, Bronte V, Tecchio C, Scapini P, Cassatella MA. CD66b-CD64dimCD115⁺ cells in the human bone marrow represent neutrophil-committed progenitors. *Nat Immunol.* 2022 May;23(5):679-691. doi: 10.1038/s41590-022-01189-z. Epub 2022 Apr 28.
24. Ferraccioli G, Gremese E, Goletti D, Petrone L, Cantini F, Ugel S, Canè S, Bronte V. Immune-Guided Therapy of COVID-19. *Cancer Immunol Res.* 2022 Apr 1;10(4):384-402. doi: 10.1158/2326-6066.CIR-21-0675.
25. Musiu C, Caligola S, Fiore A, Lamolinara A, Frusteri C, Del Pizzo FD, De Sanctis F, Canè S, Adamo A, Hofer F, Barouni RM, Grilli A, Zilio S, Serafini P, Tacconelli E, Donadello K, Gottin L, Polati E, Girelli D, Polidoro I, Iezzi PA, Angelucci D, Capece A, Chen Y, Shi ZL, Murray PJ, Chilosi M, Amit I, Biciato S, Iezzi M, Bronte V, Ugel S. Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis. *Cell Death Differ.* 2022 Feb;29(2):420-438. doi: 10.1038/s41418-021-00866-0. Epub 2021 Sep 13.
26. Del Bianco P, Pinton L, Magri S, Canè S, Masetto E, Basso D, Padovan M, Volpin F, d'Avella D, Lombardi G, Zagonel V, Bronte V, Della Puppa A, Mandruzzato S. Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients. *Front Immunol.* 2022 Jan 7;12:809826. doi: 10.3389/fimmu.2021.809826. eCollection 2021.
27. De Sanctis F, Lamolinara A, Boschi F, Musiu C, Caligola S, Trovato R, Fiore A, Frusteri C, Anselmi C, Poffe O, Cestari T, Canè S, Sartoris S, Giugno R, Del Rosario G, Zappacosta B, Del Pizzo F, Fassan M, Dugnani E, Piemonti L, Bottani E, Decimo I, Paiella S, Salvia R, Lawlor RT, Corbo V, Park Y, Tuveson DA, Bassi C, Scarpa A, Iezzi M, Ugel S, Bronte V. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. *J Immunother Cancer.* 2022 Jan;10(1):e003549. doi: 10.1136/jitc-2021-003549.
28. Perico ME, Maluta T, Conti G, Vella A, Provezza L, Cestari T, De Cao G, Segalla L, Tecchio C, Benedetti F, Santini F, Bronte V, Magnan B, Sbarbati A, Ramarli D. The Cross-Talk between Myeloid and Mesenchymal Stem Cells of Human Bone Marrow Represents a Biomarker of Aging That Regulates Immune Response and Bone Reabsorption. *Cells.* 2021 Dec 21;11(1):1. doi: 10.3390/cells11010001.
29. Aaboe Jørgensen M, Ugel S, Linder Hübbe M, Carretta M, Perez-Penco M, Weis-Banke SE, Martinenaite E, Kopp K, Chapellier M, Adamo A, De Sanctis F, Frusteri C, Iezzi M, Zocca MB, Hargbøll Madsen D, Wakatsuki Pedersen A, Bronte V, Andersen MH. Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize

- with Anti-PD-1 Checkpoint Blockade. *Cancer Immunol Res.* 2021 Nov;9(11):1316-1326. doi: 10.1158/2326-6066.CIR-21-0280. Epub 2021 Sep 13.
30. Cali B, Agnellini AHR, Cioccarelli C, Sanchez-Rodriguez R, Predonzani A, Toffolo GI, Viola A, Bronte V, Arrigoni G, Zonta F, Albertoni L, Mescoli, Marigo I, Molon B. GM-CSF Nitration is a new driver of myeloid suppressor cell activity in tumors. *Front Immunol.* 2021 Oct 5;12:7:718098. doi: 10.3389/fimmu.2021.718098. eCollection 2021.
 31. Musiu C, Caligola S, Fiore A, Lamolinare A, Frusteri C, Del Pizzo FD, De Sanctis F, Canè S, Adamo A, Hofer F, Barouni RM, Grilli A, Zilio S, Serafini P, Tacconelli E, Donadello K, Gottin L, Polati E, Girelli D, Polidoro I, Iezzi PA, Angelucci D, Capece A, Chen Y, Shi ZL, Murray PJ, Chilosi M, Amit I, Biccato S, Iezzi M, Bronte V, Ugel S. Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis. *Cell Death Differ.* 2021 Sep 13. doi: 10.1038/s41418-021-00866-0.
 32. Aaboe Jørgensen M, Ugel S, Hübbe ML, Carretta M, Perez-Penco M, Weis-Banke SE, Martinenaite E, Kopp K, Chapellier M, Adamo A, De Sanctis F, Frusteri C, Iezzi M, Zocca MB, Madsen DH, Pedersen AW, Bronte V, Andersen MH. Arginase 1-based immune modulatory vaccines induce anti-cancer immunity and synergize with anti-PD-1 checkpoint blockade. *Cancer Immunol Res.* 2021 Sep 13;canimm.0280.2021. doi: 10.1158/2326-6066.CIR-21-0280.
 33. Arcolaci A, Bronte V, Zanoni G. Immunization practices and risk of anaphylaxis: a current update, comprehensive of Covid-19 vaccination data. *Curr Opin Allergy Clin Immunol.* 2021 Oct 1;21(5):418-425. doi: 10.1097/ACI.0000000000000769.
 34. Chilosi M, Poletti V, Ravaglia C, Rossi G, Dubini A, Piciocchi S, Pedica F, Bronte V, Pizzolo G, Martignoni G, Doglioni C. The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: victims and partners in crime. *Mod Pathol.* 2021 Aug;34(8):1444-1455. doi: 10.1038/s41379-021-00808-8.
 35. Ciccocioppo R, Gibellini D, Astori G, Bernardi M, Bozza A, Chieragato K, Elice F, Ugel S, Caligola S, De Sanctis F, Canè S, Fiore A, Trovato A, Vella A, Petrova V, Amodeo G, Santimaria M, Mazzariol A, Frulloni L, Ruggeri M, Polati E, Bronte V. The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia. *Stem Cell Res Ther.* 2021 Jun 2;12(1):316. doi: 10.1186/s13287-021-02376-9. PMID: 34078447.
 36. Ugel S, Bronte V. Galectin-1 supports a dangerous liaison between monocytes and multiple myeloma. *Cancer Immunol Res.* 2021 May;9(5):488. doi: 10.1158/2326-6066.CIR-21-0242. PMID: 33941534.
 37. Canè S, Bronte V. Wnt- β -catenin as an epigenetic switcher in colonic Treg cells. *Nat Immunol.* 2021 Apr;22(4):400-401. doi: 10.1038/s41590-021-00904-6. PMID: 33753943
 38. Doglioni C, Ravaglia C, Chilosi M, Rossi G, Dubini A, Pedica F, Piciocchi S, Vizzuso A, Stella F, Maitan S, Agnoletti V, Puglisi S, Poletti G, Sambri V, Pizzolo G, Bronte V, Wells AU, Poletti V. Covid-19 interstitial pneumonia: histological and immunohistochemical features on cryobiopsies. *Respiration.* 2021 Mar 16:1-11. doi: 10.1159/000514822. PMID: 33725700.
 39. Bost P, De Sanctis F, Canè S, Ugel S, Donadello K, Castellucci M, Eyal D, Fiore A, Anselmi C, Barouni RM, Trovato R, Caligola S, Lamolinara A, Iezzi M, Facciotti F, Mazzariol A, Gibellini D, De Nardo P, Tacconelli E, Gottin L, Polati E, Schwikowski B, Amit I, Bronte V. Deciphering the state of immune silence in fatal COVID-19 patients. *Nature Communications.* 2021 Mar 05;12(1):1428. doi: 10.1038/s41467-021-21702-6.
 40. De Sanctis F, Bronte V. How to reprogram Myeloma-Associated macrophages: target IKZF1. *Cancer Immunol Res.* 2021 Mar;9(3):254. doi: 10.1158/2326-6066.CIR-21-0026.
 41. Ugel S, Canè S, De Sanctis F, Bronte V. Monocytes in the tumor microenvironment. *Annu Rev Pathol.* 2021 Jan 24;16:93-122. doi: 10.1146/annurev-pathmechdis-012418-013058. PMID: 33497262.
 42. Taus F, Salvagno G, Canè S, Fava C, Mazzaferri F, Carrara E, Petrova V, Barouni RM, Dima F, Dalbeni A, Romano S, Poli G, Benati M, Denitto S, Mansueto G, Iezzi M, Tacconelli E, Lippi G, Bronte V, Minuz P. Platelets promote thromboinflammation in SARS-CoV-2 pneumonia. *Arterioscler Thromb Vasc Biol.* 2020 Dec;40(12):2975-2989. doi: 10.1161/ATVBAHA.120.315175. Epub 2020 Oct 14. PMID: 33052054.
 43. Comment in: Megakaryocytes: Masters of Innate Immunity? Crispin PJ, Montague SJ. *Arterioscler Thromb Vasc Biol.* 2020 Dec;40(12):2812-2814. doi: 10.1161/ATVBAHA.120.315471. Epub 2020 Nov 24. PMID: 33232209.
 44. Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Canè S, Batani V, Trovato R, Fiore A, Petrova V, Hofer F, Barouni RM, Musiu C, Caligola S, Pinton L, Torroni L, Polati E, Donadello K, Friso S, Pizzolo F, Iezzi M, Facciotti F, Pelicci PG, Righetti D, Bazzoni P, Rampudda M, Comel AC, Mosaner W, Lunardi C, Olivieri O. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. *J Clin Invest.* 2020 Dec 1;130(12):6409-6416. doi:10.1172/JCI141772. PMID: 32809969.
 45. Comment in: Caring for patients in a new pandemic: the necessity and challenges of observational research. Thomas DL. *J Clin Invest.* 2020 Dec 1;130(12):6225-6227. doi: 10.1172/JCI143292. PMID: 32902413
 46. Marigo I, Trovato R, Hofer F, Ingangi V, De Sanctis F, Ugel S, Canè S, Simonelli A, Lamolinara A, Iezzi M, Fassan M, Rugge M, Boschi F, Borile G, Eisenhaure T, Sarkizova S, Lieb D, Hacohen N, Azzolin L, Piccolo S, Lawlor RT, Scarpa A, Carbogni L, Bria E, Biccato S, Murray PJ, Bronte V. Disabled homolog 2 controls prometastatic activity of tumor-associated macrophages. *Cancer Discov.* 2020 Nov;10(11):1758-1773. doi:10.1158/2159-8290.CD-20.0036. Epub 2020 Jul 10. PMID: 32651166.
 47. Croce M, Damonte P, Morini M, Pigozzi S, Chiossone L, Vacca P, Bronte V, Barbieri O, Astigiano S. Increased Arginase1 expression in tumor microenvironment promotes mammary carcinogenesis via multiple mechanisms. *Carcinogenesis.* 2020 Dec 31;41(12):1695-1702. doi:10.1093/carcin/bgaa063. PMID: 32614387.
 48. Cancio M, Ciccocioppo R, Rocco PRM, Levine BL, Bronte V, Bollard CM, Weed D, Boelens JJ, Hanley PJ. Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. *Cytotherapy.* 2020 Sep;22(9):474-481. doi:10.1016/j.cyt.2020.04.100. Epub 2020 May 7. PMID: 32565132.
 49. De La Fuente A, Zilio S, Caroli J, Van Simaey D, Mazza EMC, Ince TA, Bronte V, Biccato S, Weed DT, Serafini P.

- Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy. *Sci Transl Med.* 2020 Jun 17;12(548):eaav9760. doi:10.1126/scitranslmed.aav9760. PMID: 32554710.
50. Porta C, Consonni FM, Morlacchi S, Sangaletti S, Bleva A, Totaro MG, Larghi P, Rimoldi M, Tripodo C, Strauss L, Banfi S, Storto M, Pressani T, Rimassa L, Tartari S, Ippolito A, Doni A, Soldà G, Duga S, Piccolo V, Ostuni R, Natoli G, Bronte V, Balzac F, Turco E, Hirsch E, Colombo MP, Sica A. Tumor-derived prostaglandin E2 promotes p50 NF- κ B-dependent differentiation of monocytic MDSCs. *Cancer Res.* 2020 Jul 1;80(13):2874-2888. doi: 10.1158/0008-5472.CAN-19-2843. Epub 2020 Apr 7. PMID: 32265223.
 51. Vella A, D'Aversa E, Api M, Breveglieri G, Allegri M, Giacomazzi A, Busilacchi EM, Fabrizzi B, Cestari T, Sorio C, Bedini G, D'Amico G, Bronte V, Poloni A, Benedetti A, Bovo C, Corey SJ, Borgatti M, Cipolli M, Bezzeri V. mTOR and STAT3 pathway hyper-activation is associated with elevated Interleukin-6 levels in patients with Shwachman-Diamond Syndrome: further evidence of Lymphoid Lineage Impairment. *Cancers (Basel).* 2020 Mar 5;12(3):597. doi:10.3390/cancers12030597. PMID:32150944.
 52. Pinton L, Magri S, massetto E, Vettore M, Schibuola I, Ingangi V, Marigo I, Matha K, Benoit JP, Della Puppa A, Bronte V, Lollo G, Mandruzzato S. Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules. *J Nanobiotechnology.* 2020 Feb 17;18(1):31. doi:10.1186/s12951-020-00589-3. PMID: 32066449.
 53. Bronte V. Macrophages instruct aberrant glycosylation in colon cancer by chemokine and cytokine signals. *Cancer Immunol Res.* 2020 Feb;8(2):160. doi:10.1158/2326-6066.CIR-19-1005. PMID: 32015012.
 54. Comment in: Cross-talk between Colon Cells and Macrophages Increases ST6GALNAC1 and MUC1-sTn Expression in Ulcerative Colitis and Colitis-Associated Colon Cancer. Kvorjak M, Ahmed Y, Miller ML, Sriram R, Coronello C, Hashash JG, Hartman DJ, Telmer CA, Miskov-Zivanov N, Finn OJ, Cascio S. *Cancer Immunol Res.* 2020 Feb;8(2):167-178. doi: 10.1158/2326-6066.CIR-19-0514. Epub 2019 Dec 12. PMID: 31831633.
 55. Halaby MJ, Hezaveh K, Lamorte S, Ciudad MT, Kloetgen A, MacLeod BL, Guo M, Chakravarthy A, Medina TDS, Ugel S, Tsigos A, Bronte V, Munn DH, Pugh TJ, De Carvalho DD, Butler MO, Ohi PS, Brooks DG, McGaha TL. GCN2 drives macrophages and MDSC function and immunosuppression in the tumor microenvironment. *Sci Immunol.* 2019 Dec 13;4(45):eaax8189. doi:10.1126/sciimmunol.aax8189. PMID: 31836669.
 56. Bronte V. Close to the bone; tissue-specific checkpoint immunotherapy evasion. *Cell.* 2019 Nov 14;179(5):1010-1012. doi:10.1016/j.cell.2019.10.022. PMID: 31730845.
 57. Comment in: Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, Sharma P. *Cell.* 2019 Nov 14;179(5):1177-1190.e13. doi: 10.1016/j.cell.2019.10.029. PMID: 31730856.
 58. Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiew S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smith MJ, Soria JC, Kroemer G, Bronte V, Wargo J, Zitvogel L. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. *Cell Res.* 2019 Oct 29;10(10):846-861. doi:10.1038/s41422-019-0224-x. Epub 2019 Sep 3. PMID: 31481761.
 59. Trovato R, Fiore A, Sartori S, Canè S, Giugno R, Cascione L, Paiella S, Salvia R, De Sanctis F, Poffe O, Anselmi C, Hofer F, Sartoris S, Piro G, Carbone C, Corbo V, Lawlor R, Solito S, Pinton L, Mandruzzato S, Bassi C, Scarpa A, Bronte V, Ugel S. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. *J Immunother Cancer.* 2019 Sep 18;7(1):255. doi:10.1186/s40425-019-0734-6. PMID: 31533831.
 60. Koehn BH, Saha A, McDonald-Hyman C, Loschi M, Thangavelu G, Ma L, Zaiken M, Dysthe J, Krepps W, Panthera J, Hippen K, Jameson SC, Miller JS, Cooper MA, Farady CJ, Iwawaki T, Ting JP, Serody JS, Murphy WJ, Hill GR, Murray PJ, Bronte V, Munn DH, Zaiser R, Blazar BR. Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. *Blood.* 2019 Nov 7;134(19):1670-1682. doi:10.1182/blood.2019001950. PMID: 31533918.
 61. Comment in: We didn't start the fire, MDSC inflammasome signalling in GVHD.
 62. Buxbaum NP. *Blood.* 2019 Nov 7;134(19):1570-1572. doi: 10.1182/blood.2019003247. PMID: 31698421.
 63. Filippini D, Agosto S, Delfino P, Simbolo M, Piro G, Rusev B, Veghini L, Cantù C, Lupo F, Ugel S, De Sanctis F, Bronte V, Milella M, Tortora G, Scarpa A, Carbone C, Corbo V. Immuno-evolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. *Sci Rep.* 2019 Aug 22;9(1):12286. doi:10.1038/s41598-019-48663-7. PMID: 31439856.
 64. Canè S, Ugel S, Trovato R, Marigo I, De Sanctis F, Sartoris S, Bronte V. The Endless Saga of Monocyte Diversity. *Front Immunol.* 2019 Aug 6;10:1786. doi:10.3389/fimmu.2019.01786. eCollection 2019. PMID: 31447834.
 65. Fleming V, Hu X, Weller C, Weber R, Groth C, Riester Z, Hüser L, Sun Q, Nagibin V, Kirschning C, Bronte V, Utikal J, Altevogt P, Umansky V. Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. *Cancer Res.* 2019 Sep 15; 79(18):4715-4728. doi:10.1158/0008-5472.CAN-19-0053. Epub 2019 Jul 23. PMID: 31337655.
 66. Bronte V. Deciphering macrophage and monocyte code to stratify human breast cancer patients. *Cancer Cell.* 2019 Apr 15;35(4):538-539. doi:10.1016/j.ccell.2019.03.010. PMID: 30991022.
 67. Comment in: Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, Fidanza A, Lopez-Yrigoyen M, Millar MR, Urman A, Ai Z, Spellman PT, Hwang ES, Dixon JM, Wiechmann L, Coussens LM, Smith HO, Pollard JW. *Cancer Cell.* 2019 Apr

- 15;35(4):588-602.e10. doi: 10.1016/j.ccell.2019.02.009. Epub 2019 Mar 28. PMID: 30930117.
68. Bertelli G, Trovato R, Ugel S, Bria E, Milella M, Bronte V, Pilotto S. Characterization of myeloid-derived suppressor cells in a patient with lung adenocarcinoma undergoing durvalumab treatment: a case report. *Clin Lung Cancer*. 2019 Jul 20;(4):e514-e516. doi:10.1016/j.clc.2019.04.013. Epub 2019 Apr 28. PMID: 31122866.
69. Solito S, Pinton L, De Sanctis F, Ugel S, Bronte V, Mandruzzato S, Marigo I. Methods to measure MDSC immune suppressive activity in vitro and in vivo. *Curr Protoco Immunol*. 2019 Feb;124(1):e61. doi:10.1002/cpim.61. Epub 2018 Oct 10. PMID: 30303619.
70. Travelli C, Consonni FM, Sangaletti S, Storto M, Morlacchi S, Grolla AA, Galli U, Tron GC, Portararo P, Rimassa L, Pressiani T, Mazzone M, Trovato R, Ugel S, Bronte V, Tripodo C, Colombo MP, Genazzani AA, Sica A. Nicotinamide phosphoribosyltransferase (NAMPT) acts as a metabolic gate for mobilization of myeloid-derived suppressor cells. *Cancer Res*. 2019 Apr 15;79(8):1938-1951. doi:10.1158/0008-5472.CAN-18-1544. Epub 2019 Feb 18. PMID: 30777853.
71. Ledo AM, Sasso MS, Bronte V, Marigo I, Boyd BJ, Garcia-Fuentes M, Alonso MJ. Co-delivery of RNAi and chemokine by polyarginine nanocapsules enables the modulation of myeloid-derived suppressor cells. *J Control Release*. 2019 Feb 10;295:60-73. doi:10.1016/j.conrel.2018.12.041. Epub 2018 Dec 26. PMID: 30593832.
72. Bezzerri V, Vella A, Di Gennaro G, Ortolani R, Nicolis E, Cesaro S, Fabrizio B, Bronte V, Corey SJ, Cipolli M. Peripheral blood immunophenotyping in a large cohort of patients with Shwachman-Diamond syndrome. *Pediatr Blood Cancer*. 2019 May;66(5):e27597. doi:10.1002/pbc.27597. Epub 2019 Jan 2. PMID: 30604473.
73. Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, Melisi D, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Biciato S, Blazar BR, Sahin U, Murray PJ, Bronte V. Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. *Nat. Commun*. 2018 Dec 5;9(1):5193. doi:10.1038/s41467-018-07654-4. PMID: 30518925.
74. Bronte V. The expanding constellation of immune checkpoints: a DNAMic control by CD155. *J Clin Invest*. 2018 Jun 1;128(6):2199-2201. doi:10.1172/JCI121229. Epub 2018 May 14. PMID: 29757194.
75. Comment in: CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. Li XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ. *J Clin Invest*. 2018 Jun 1;128(6):2613-2625. doi: 10.1172/JCI98769. Epub 2018 May 14. PMID: 29757192.
76. Bronte V. The mesenchymal and myeloid regulation of immunity: power is nothing without control. *Semin Immunol*. 2018 Feb;35:1-2. doi:10.1016/j.smim.2018.03.001. PMID: 29566937.
77. Sharma MD, Rodriguez PC, Koehn BH, Baban B, Cui Y, Guo G, Shimoda M, Pacholczyk R, Shi H, Lee EJ, Xu H, Johnson TS, He Y, Mergoub T, Venable C, Bronte V, Wolchok JD, Blazar BR, Munn DH. Activation of p53 in myeloid precursor cells controls differentiation into immunogenic Ly6c+CD103+monocytic cells in tumors. *Immunity*. 2018 Jan 16;48(1):91-106.e6. doi:10.1016/j.immuni.2017.12.014. PMID: 29343444.
78. Comment in: mDCs, Less Problems. Gardner A, Ruffell B. *Immunity*. 2018 Jan 16;48(1):6-8. doi: 10.1016/j.immuni.2017.12.017. PMID: 29343441.
79. Bronte V. From Oncogene interference to neutrophil immune modulation. *Immunity*. 2017 Oct 17;47(4):613-615. doi:10.1016/j.immuni.2017.10.005. PMID: 29045894.
80. Comment in: Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T, Hölzel M. *Immunity*. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012. PMID: 2904590.
81. Sandri S, De Sanctis F, Lamolinara A, Boschi F, Poffe O, Trovato R, Fiore A, Sartori S, Sbarbati A, Bondanza A, Cesaro S, Krampfer M, Scupoli MT, Nishimura MI, Iezzi M, Sartoris S, Bronte V, Ugel S. Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. *Oncotarget*. 2017 May 23;8(50):86987-87001. doi:10.18632/oncotarget.18115. eCollection 2017 Oct 20. PMID: 29152058.
82. Mondanelli G, Ugel S, Grohmann U, Bronte V. The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. *Curr Opin Pharmacol*. 2017 Aug;35:30-39. doi:10.1016/j.coph.2017.05.002. Epub 2017 May 26. PMID: 28554057.
83. Gnjatich S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tenneau I, Wigginton JM, Butterfield LH. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. *J Immunother Cancer*. 2017 May 16;5:44. doi:10.1186/s40425-017-0243-4. eCollection 2017. PMID: 28515944.
84. Zilio S, Vella JL, De la Fuente AC, Daftarian PM, Weed DT, Kaifer A, Marigo I, Leone K, Bronte V, Serafini P. 4PD functionalized dendrimers: a flexible tool for in vivo gene silencing of tumor-educated myeloid cells. *J Immunol*. 2017 May 15;198(10):4166-4177. doi:10.4049/jimmunol.1600833. Epub 2017 Apr 10. PMID: 28396317.
85. Mondanelli G, Bianchi R, Pallotta MT, Orabona C, Albini E, Iacono A, Belladonna ML, Vacca C, Fallarino F, Macchiarulo A, Ugel S, Bronte V, Gevi F, Zolla L, Verhaar A, Peppelenbosch M, Mazza EM, Biciato S, Laouar Y, Santambrogio L, Puccetti P, Volpi C, Grohmann U. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. *Immunity*. 2017 Feb 21;46(2):233-244. doi:10.1016/j.immuni.2017.01.005. Epub 2017 Feb 14. PMID: 28214225.
86. Trento C, Marigo I, Pievani A, Galleu A, Dolcetti L, Wang CY, Serafini M, Bronte V, Dazzi F. Bone marrow mesenchymal

- stromal cells induce nitric oxide synthase-dependent differentiation of CD11b+ cells that expedite hematopoietic recovery. *Haematologica*. 2017 May;102(5):818-825. doi:10.3324/haematol.2016.155390. Epub 2017 Feb 9. PMID: 28183849.
87. Perico ME, Grasso S, Brunelli M, Martigoni G, Munari E, Moiso E, Fracasso G, Cestari T, Naim HY, Bronte V, Colombatti M, Ramarli D. Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo". *Oncotarget*. 2016 Nov 8;7(45):74189-74202. doi:10.18632/oncotarget.1244. PMID: 27713116.
 88. Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EM, Biciato S, Galon J, Murry PJ, Bronte V. T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. *Cancer Cell*. 2016 Oct 10;30(4):651. doi:10.1016/j.ccell.2016.09.009. PMID:27728809.
 89. Comment in: Tipping the Balancing ACT. Pilon-Thomas S, Ruffell B. *Cancer Cell*. 2016 Sep 12;30(3):367-368. doi: 10.1016/j.ccell.2016.08.012. PMID: 27622327.
 90. Bronte V, Tortora G. Adipocytes and neutrophils give a helping hand to pancreatic cancers. *Cancer Discov*. 2016 Aug;6(8):821-3. doi:10.1158/2159-8290.CD-16-0682. PMID: 27485002.
 91. Comment in: Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, Ng MR, Nia HT, Grahovac J, Kao S, Babykutty S, Huang Y, Jung K, Rahbari NN, Han X, Chauhan VP, Martin JD, Kahn J, Huang P, Desphande V, Michaelson J, Michelakos TP, Ferrone CR, Soares R, Boucher Y, Fukumura D, Jain RK. *Cancer Discov*. 2016 Aug;6(8):852-69. doi: 10.1158/2159-8290.CD-15-1177. Epub 2016 May 31. PMID: 27246539.
 92. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nat Commun*. 2016 Jul 6;7:12150. doi:10.1038/ncomms12150. PMID:27381735.
 93. Sandri S, Bobisse S, Moxley K, Lamolinare A, De Sanctis F, Boschi F, Sbarbati A, Fracasso G, Ferrarini G, Hendriks RW, Cavallini C, Scrupoli MT, Sartoris S, Iezzi M, Nishimura MI, Bronte V, Ugel S. Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies. *Cancer Res*. 2016 May 1;76(9):2540-51. doi:10.1158/0008-5472.CAN-15-2318. PMID: 27197263.
 94. Sasso MS, Lollo G, Pitorre M, Solito S, Pinton L, Valpione S, Bastiat G, Mandruzzato S, Bronte V, Marigo I, Benoit JP. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. *Biomaterials*. 2016 Jul;96:47-62. doi:10.1016/j.biomaterials.2016.04.010. Epub 2016 Apr 22. PMID: 27135716.
 95. Bronte V, Bria E. Interfering with CCL5/CCR5 at the tumor-stroma interface. *Cancer Cell*. 2016 Apr 11;29(4):437-439. doi:10.1016/j.ccell.2016.03.019. PMID: 27070698.
 96. Comment in: Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetlerlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfield C, Grabe N, Falk CS, Jaeger D. *Cancer Cell*. 2016 Apr 11;29(4):587-601. doi: 10.1016/j.ccell.2016.03.005. PMID: 27070705.
 97. Arina A, Corrales L, Bronte V. Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. *Semin Immunol*. 2016 Feb; 28(1):54-63. doi:10.1016/j.smim.2016.01.02. Epub 2016 Feb 10. PMID: 26872631.
 98. Mandruzzato S, Brandau S, Britten CM, Bronte V, Damuzzo V, Gouttefangeas C, Maurer D, Ottensmeier C, Van Der Burg SH, Welters MJ, Walter S. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: result from an interim study. *Cancer Immunol Immunother*. 2016 Feb; 65(2):161-9. doi:10.1007/s00262-015-1782-5. Epub 2016 Jan 4. PMID: 26728481.
 99. Pinton L, Solito S, Damuzzo V, Francescato S, Pozzuoli A, Berizzi A, Mocellin S, Rossi CR, Bronte V, Mandruzzato S. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. *Oncotarget* 2016 Jan 12; 7(2):1168-84. doi:10.18632/oncotarget.6662. PMID: 26700461.
 100. Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. *Curr Opin Immunol*. 2016 Apr;39:1-6. doi:10.1016/j.coi.2015.10.009. Epub 2015 Nov 21. PMID: 26609943.
 101. Massari F, Ciccarese C, Calò A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, Ghimenton C, Bertoldo F, Scarpa A, Sperandino N, Porta C, Bronte V, Chilosì M, Bogina G, Zamboni G, Tortora G, Samaratunga H, Martignoni G, Brunelli M. Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis. *Target Oncol*. 2016 Jun;11(3):345-51. doi:10.1007/s11523-015-0396-3. PMID: 26566945.
 102. Astigiano S, Morini M, Damonte P, Fraternali Orcioni G, Cassanello M, Puglisi A, Noonan DM, Bronte V, Barbieri O. Transgenic Mice overexpressing arginase 1 in monocytic cell lineage are affected by lympho-myeloproliferative disorder and disseminated intravascular coagulation. *Carcinogenesis*. 2015 Nov;36(11):1354-62. doi:10.1093/carcin/bgv129. Epub 2015 Sep 10. PMID: 26363032.
 103. Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. *J Clin Invest*. 2015 Sep;125(9):3365-76. doi:10.1172/JCI80006. Epub 2015 Sep 1. PMID: 26325033.
 104. Zhu Z, Cuss SM, Singh V, Gurusamy D, Shoe JL, Leighty R, Bronte V, Hurwitz AA. CD4+T cell help selectively enhances high-avidity tumor antigen-specific CD8+T cells. *J Immunol*. 2015 Oct 1;195(7):3482-9. doi:10.4049/jimmunol.1401571.

Epub 2015 Aug 28. PMID: 26320256.

105. Ochando J, Conde P, Bronte V. Monocyte-derived suppressor cells in transplantation. *Curr Transplant Rep*. 2015;2(2):176-83. doi:10.1007/s40472-015-0054-9. PMID: 26301174.
106. Koehn BH, Apostolova P, Haverkamp JM, Miller JS, McCullar V, Tolar J, Munn DH, Murphy WJ, Brickey WJ, Serody JS, Gabrilovich DI, Bronte V, Murray PJ, Ting JP, Zeiser R, Blazar BR. GvHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. *Blood*. 2015 Sep 24;126(13):1621-8. doi:10.1182/blood-2015-03-634691. Epub 2015 Aug 11. PMID: 26265697.
107. De Sanctis F, Solito S, Ugel S, Molon B, Bronte V, Marigo I. MDSCs in cancer: conceiving new prognostic and therapeutic targets. *Biochim Biophys Acta*. 2016 Jan;1865(1):35-48. doi:10.1016/j.bbcan.2015.08.001. Epub 2015 Aug 6. PMID: 26255541.
108. Norman MZ, Janji B, Hu S, Wu JC, Martelli F, Bronte V, Chouaib S. Tumor promoting effects of myeloid derived suppressor cells are potentiated by hypoxia-induced expression of miR-210. *Cancer Res*. 2015 Sep 15;75(18):3771-87. doi:10.1158/0008-5472.CAN-15-0405. Epub 2015 Jul 23. PMID: 26206559.
109. Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calì A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, Bronte V, Scarpa A, Bria E, Tortora G. Differential activity of nivolumab, pembrolizumab and MPDL3208A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. *PLoS One*. 2015 Jun 18; 10(6):e0130142. doi:10.1371/journal.pone.0130142. eCollection 2015. PMID: 26086854.
110. Conde P, Rodriguez M, Van der Touw W, Jimenez A, Burns M, Miller J, Brahmachary M, Chen HM, Boros P, Rausell-Palamos F, Yun TJ, Riquelme P, Rastrojo A, Aguado B, Stein-Streilein J, Tanaka M, Zhou L, Zhang L, Lowary TL, Ginhoux F, Park CG, Cheong C, Brody J, Turley SJ, Lira SA, Bronte V, Gordon S, Heeger PS, Merad M, Hutchinson J, Chen SH, Ochando J. DC-SIGN(+) Macrophages control the induction of transplantation tolerance. *Immunity*. 2015 Jun 16;42(6):1143-58. doi:10.1016/j.immuni.2015.05.009. Epub 2015 Jun 9. PMID: 26070485.
111. Comment in: DC-SIGN: The Strange Case of Dr. Jekyll and Mr. Hyde. Garcia-Vallejo JJ, van Kooyk Y. *Immunity*. 2015 Jun 16;42(6):983-5. doi: 10.1016/j.immuni.2015.05.021. PMID: 26084017.
112. Mazzocco M, Martini M, Rosato A, Stefani E, Matucci A, Dalla Santa S, De Sanctis F, Ugel S, Sandri S, Ferrarini G, Cestari T, Ferrari S, Zanollo P, Bronte V, Sartoris S. Autologous cellular vaccine overcomes cancer immunoeediting in a mouse model of myeloma. *Immunology*. 2015 Sep;146(1):33-49. doi:10.1111/imm.12477. Epub 2015 Jun 15. PMID: 25959091.
113. Calì B, Ceolin S, Ceriani F, Bortolozzi M, Agnellini AH, Zorzi V, Predonzani A, Bronte V, Molon B, Mammano F. Critical role of gap junction communication, calcium and nitric oxide signaling in bystander responses to focal photodynamic injury. *Oncotarget*. 2015 Apr 30;6(12):10161-74. doi:10.18632/oncotarget.3553. PMID: 25868859.
114. Arina A, Bronte V. Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. *Curr Opin Immunol*. 2015 Apr;33:120-5. doi:10.1016/j.coi.2015.02.006. Epub 2015 Feb 27. PMID: 25728992
115. Bronte V, Murray PJ. Understanding local macrophage phenotypes in disease: modulating macrophage function to treat cancer. *Nat Med*. 2015 Feb;21(2):117-9. doi:10.1038/nm.3794. PMID: 25654601.
116. Mazza EMC, Zoso A, Mandruzzato S, Bronte V, Serafini P, Inverardi L, Biciato S. Gene expression profiling of human fibrocytic myeloid-derived suppressor cells (f-MDSCs). *Genom Data*. 2014 Oct 31;2:389-92. doi:10.1016/j.gdata.2014.10.018. eCollection 2014 Dec. PMID: 26484135.
117. Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, Bronte V, Mandruzzato S. Complexity and challenges in defining myeloid-derived suppressor cells. *Cytometry B Clin Cytom*. 2014 Nov 26. doi: 10.1002/cytob.21206. online ahead of print. PMID: 25425222.
118. Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, Green DR, Opferman JT, Murray PJ. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. *Immunity*. 2014 Dec 18;41(6):947-59. doi:10.1016/j.immuni.2014.10.020. Epub 2014 Dec 11. PMID: 25500368.
119. Bronte V. Tumors STING adaptive antitumor immunity. *Immunity*. 2014 Nov 20; 41(5):679-81. doi:10.1016/J.immuni.2014.11.004. Epub 2014 Nov 20. PMID: 25517609.
120. Comment in:
121. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Woo SR, Fierres MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML, Gajewski TF. *Immunity*. 2014 Nov 20;41(5):830-42. doi: 10.1016/j.immuni.2014.10.017. Epub 2014 Nov 5. PMID: 25517615.
122. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR. *Immunity*. 2014 Nov 20;41(5):843-52. doi: 10.1016/j.immuni.2014.10.019. Epub 2014 Nov 6. PMID: 25517616.
123. Ricci C, Mota C, Moscato S, D'Alessandro D, Ugel S, Sartoris S, Bronte V, Boggi U, Campani D, Funel N, Morini L, Danti S. Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. *Biomater*. 2014;4:e955386. doi:10.4161/21592527.2014.955386. PMID: 25482337.
124. Schoenen H, Huber A, Sonda N, Zimmermann S, Jantsch J, Lepenies B, Bronte V, Lang R. Differential control of m1ncle-dependent cord factor recognition and macrophage responses by the transcription factors C/EBP β and HIF1 α . *J Immunol*. 2014 Oct 1;193(7):3664-75. doi:10.4049/jimmunol.1301593. Epub 2014 Aug 25. PMID: 25156364.
125. Zoso A, Mazza EM, Biciato S, Mandruzzato S, Bronte V, Serafini P, Iverardi L. Human fibrocytic myeloid-derived

- suppressor cells express IDO and promote tolerance via Treg-cell expansion. *Eur J Immunol.* 2014 Nov;44(11):3307-19. doi: 10.1002/eji.201444522. Epub 2014 Oct 18. PMID: 25113564.
126. Bronte V. Tumor cells hijack macrophages via lactic acid. *Immunol Cell Biol.* 2014 Sep;92(8):647-9. doi:10.1002/icb.2014.67. Epub 2014 Aug 5. PMID: 25091608.
 127. Comment in: Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, Cline GW, Phillips AJ, Medzhitov R. *Nature.* 2014 Sep 25;513(7519):559-63. doi: 10.1038/nature13490. Epub 2014 Jul 13. PMID: 25043024.
 128. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. *Ann N Y Acad Sci.* 2014 Jun;1319:47-65. doi:10.1111/nyas.12469. PMID: 24965257.
 129. Noman MZ, Desantis G, Janji B, Hasmin M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1 α , and its blockade under hypoxia enhanced MDSC-mediated T cell activation. *J Exp Med.* 2014 May 5;211(5):781-90. doi:10.1084/jem.20131916. Epub 2014 Apr 28. PMID: 24778419.
 130. Ruggero k, Guffanti A, Corradin A, Sharma VK, De Bellis G, Corti G, Grassi A, Zanovello P, Bronte V, Ciminale V, D'Agostino DM. Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. *J Virol.* 2014 Apr;88(7):3612-22. doi:10.1128/JVI.02823-13. Epub 2014 Jan 8. PMID: 24403582.
 131. Bianchi G, Vuerich M, Pellegatti P, Marimpietri D, Emionite L, Marigo I, Bronte V, Di Virgilio F, Pistoia V, Raffaghello L. ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. *Cell Death Dis.* 2014 Mar 20;5(3):e1135. doi:10.1038/cddis.2014.109. PMID: 24651438.
 132. De Sanctis F, Sandri S, Ferrarini G, Pagliarello I, Sartoris S, Ugel S, Marigo I, Molon B, Bronte V. The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment. *Front Immunol.* 2014 Feb 24;5:69. doi:10.3389/fimmu.2014.00069. eCollection 2014. PMID: 24605112.
 133. Bronte V, Pittet MJ. The spleen in local and systemic regulation of immunity. *Immunity.* 2013 Nov 14;39(5):806-18. doi:10.1016/j.immuni.2013.10.010. PMID: 24238338.
 134. Sonda N, Simonato F, Peranzoni E, Cali B, Bortoluzzi S, Bisognin A, Wang E, Marincola FM, Naldini L, Gentner B, Trautwein C, Sackett SD, Zanovello P, Molon B, Bronte V. miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. *Immunity.* 2013 Jun 27;38(6):1236-49. doi:10.1016/j.immuni.2013.06.004. PMID: 23809164.
 135. Hickman HD, Reynoso GV, Ngudiankama BF, Rubin EJ, Magadàn JG, Cush SS, Gibbs J, Molon B, Bronte V, Bennink JR, Yewdell JW. Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. *Cell Host Microbe.* 2013 Feb 13;13(2):155-68. doi:10.1016/j.chom.2013.01.004. PMID: 23414756.
 136. Comment in: Getting in front and behind the enemy lines to counter virus infection. Lev A, Sigal L. *Cell Host Microbe.* 2013 Feb 13;13(2):121-2. doi: 10.1016/j.chom.2013.01.013. PMID: 23414751.
 137. Schmidt K, Zilio S, Schmollinger JC, Bronte V, Blankenstein T, Willmsky G. Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. *Blood.* 2013 Mar 7;121(10):1740-8. doi:10.1182/blood-2012-06-436568. Epub 2013 Jan 10. PMID: 23305737.
 138. Beghini A, Corlazzoli F, Del Giacco L, Re M, Lazzaroni F, Brioschi M, Valentini G, Ferrazzi F, Ghilardi A, Righi M, Turrini M, Mignardi M, Cesana C, Bronte V, Nilsson M, Morra E, Cairoli R. Regeneration-associated WNT signaling is activated in long-term reconstituting AC133bright acute myeloid leukemia cells. *Neoplasia.* 2012 Dec;14(12):1236-48. doi:10.1593/neo.121480. PMID: 23308055.
 139. Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, Ochando JC, Cabrelle A, Mandruzzato S, Bronte V. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. *Cell Rep.* 2012 Sep 27;2(3):628-39. doi:10.1016/j.celrep.2012.08.006. Epub 2012 Sep 6. PMID: 22959433.
 140. Hammami I, Chen J, Bronte V, Decrescenzo G, Jolicoeur M. L-glutamine is a key parameter in the immunosuppression phenomenon. *Biochem Biophys Res Commun.* 2012 Sep 7;425(4):724-9. doi:10.1016/j.bbrc.2012.07.139. Epub 2012 Aug 1. PMID: 22885179.
 141. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritzsche J, Mahr A, Maurer D, Vass V, Trautwein C, Levandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Bidermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirawaka K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja h. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with no longer patient survival. *Nat Med.* 2012 Aug;18(8):1254-61. doi:10.1038/nm.2883. Epub 2012 Jul 29. PMID: 22842478.
 142. Viola A, Sarukhan A, Bronte V, Molon B. The pros and cons of chemokines in tumor immunology. *Trends Immunol.* 2012 Oct;33(10):496-504. doi:10.1016/j.it.2012.05.007. Epub 2012 Jun 20. PMID: 22726608.
 143. Hammami I, Chen J, Murschel F, Bronte V, De Crescenzo G, Jolicoeur M. Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. *BMC Cell Biol.* 2012 Jul 4;13:18. doi:10.1186/1471-2121-13-18. PMID: 22762146.
 144. Molon B, Viola A, Bronte V. Smoothing T cell roads to the tumor: chemokine post-translational regulation. *Oncoimmunology.* 2012 May 1;1(3):390-392. doi:10.4161/onci.19069. PMID: 22737626.
 145. Hammami I, Bertrand M, Chen J, Bronte V, De Crescenzo G, Jolicoeur M. Nitric oxide affects immune cells bioenergetics: long-term effects of nitric-oxide derivatives on leukaemic jurkat cell metabolism. *Immunobiology.* 2012 Aug;217(8):808-15. doi:10.1016/j.imbio.2012.05.005. Epub 2012 May 11. PMID: 22656888.
 146. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumors. *Nat Rev Immunol.*

- 2012 Mar 22;12(4):253-68. doi:10.1038/nri3175. PMID: 22437938.
147. Montero AJ, Diaz-Montero CM Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. *J Immunother*. 2012 Feb-Mar;35(2):107-15. doi: 10.1097/CJI.0b013e318242169f PMID: 22306898.
 148. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, Garrett-Mayer E, Montero AJ, Bronte V, Mandruzzato S. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. *Blood*. 2011 Aug 25;118(8):2254-65. doi:10.1182/blood-2010-12-325753. Epub 2011 Jul 6. PMID: 21734236.
 149. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, De Palma A, Mauri P, Monegal A, Rescigno M, Savino B, Colombo P, Jonjic N, Pecanic S, Lazzarotto L, Fruttero R, Gasco A, Bronte V, Viola A. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. *J Exp Med*. 2011 Sep 26;208(10):1949-62. doi:10.1084/jem.20101956. Epub 2011 Sep 19. PMID:21930770.
 150. Kasic T, Colombo P, Soldani C, Wang CM, Miranda E, Roncalli V, Bronte V, Viola A. Modulation of human T cell functions by reactive nitrogen species. *Eur J Immunol*. 2011 Jul;41(7):1843-9. doi:10.1002/eji.201040868. Epub 2011 Jun 7. PMID: 21480210.
 151. Ghisi M, Corradin A, basso K, Frasson C, Serafin V, Mukherjee S, Mussolin L, Ruggero K, Bonanno L, Guffanti A, De Bellis G, Gerosa G, Stellin G, D'Agostino DM, Basso G, Bronte V, Indracollo S, Amadori A, Zanovello P. Modulation of micro RNA expression in human T-cell development: targeting of Notch3 by miR-150. *Blood* 2011 Jun 30;117(26):7053-62. doi:10.1182/blood-2010-12-326629. Epub 2011 Jun May 6. PMID: 21551231.
 152. Solito S, Bronte V, Mandruzzato S. Antigen specificity of immune suppression by myeloid-derived suppressor cells. *J Leukoc Biol*. 2011 Jul;90(1):31-6. doi:10.1189/jlb.0111021. Epub 2011 Apr 12. PMID: 21486906.
 153. Bronte V. Tolerogenic pDCs: spotlight on Foxo3. *J Clin Invest*. 2011 Apr;121(4):1247-50. doi:10.1172/JCI57190. Epub 2011 Mar 23. PMID: 21436582.
 154. Hammami I, Chen J, Bronte V, De Crescenzo G, Jolicoeur M. Myeloid-derived suppressor cells exhibit two bioenergetic steady-states in vitro. *J Biotechnol*. 2011 Mar 10;152(1-2):43-8. doi:10.1016/j.jbiotec.2011.01.009. Epub 2011 Jan 22. PMID: 21262283.
 155. Chioda M, Peranzoni E, Desantis G, Papalini F, Falisi E, Solito S, Mandruzzato S, Bronte V. Myeloid cell diversification and complexity: an old concept with new turns in oncology. *Cancer Metastasis Rev*. 2011 Mar; 30(1):27-43. doi:10.1007/s10555-011-9268-1. PMID: 21267772.
 156. Ramonda R, Musacchio E, Campana C, Frigato M, Frallonardo P, Barbieri V, Piccoli A, Valvason C, Bronte V, Zanovello P, Punzi L. Immunogenetic aspects of erosive osteoarthritis of the hand in patients from northern Italy. *Scand J Rheumatol*. 2011 Mar;40(2):139-44. doi:10.3109/03009742.2010.507216. Epub 2010 Oct 5. PMID: 20919945.
 157. Rotondo R, Bertolotto M, Barisione G, Astigiano S, Mandruzzato S, Ottonello L, Dallegri F, Bronte V, Ferrini S, Barbieri O. Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. *J LEukoc Biol*. 2011 May;89(5):721-7. doi:10.1189/jlb.1109737. Epub 2011 Feb 17. PMID: 21330347.
 158. Sonda N, Chioda M, Zilio S, Simonato F, Bronte V. Transcription factors in myeloid-derived suppressor cell generation. *Curr Opin Immunol*. 2011 Apr;23(2):279-85. doi:10.1016/j.coi.2010.12.006. Epub 2011 Jan 10. PMID: 21227670.
 159. Adeegbe D, Serafini P, Bronte V, Zoso A, Ricordi C, Inverardi L. In vivo induction of myeloid suppressor cells and CD4⁺Foxp3⁺ T regulatory cells prolongs skin allograft survival in mice. *Cell Transplant*. 2011;20(6):941-54. doi:10.3727/096368910X540621. Epub 2010 Nov 5. PMID: 21054938.
 160. Fernández A, Mesa C, Marigo I, Dolcetti L, Clavell M, Oliver L, Fernández LE, Bronte V. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. *J Immunol*. 2011 Jan 1;186(1):264-74. doi:10.4049/jimmunol.1001465. Epub 2010 Dec 6. PMID: 21135171.
 161. Dolcetti L, Peranzoni E, Bronte V. Measurement of myeloid cell immune suppressive activity. *Curr Protoc Immunol*. 2010 Nov;Chapter 14:Unit 14.17. doi:10.1002/0471142735.im1417s91. PMID: 21053303.
 162. Di Camillo B, Sanavia T, Iori E, Bronte V, Roncaglia E, Maran A, Avogaro A, Toffolo G, Cobelli C. The transcriptional response in human umbilical vein endothelial cells exposed to insulin: a dynamic gene expression approach. *PLoS One*. 2010 Dec 22;5(12):e14390. doi:10.1371/journal.pone.0014390. PMID: 21203503.
 163. Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, Ugel S, Cingarlini S, Bronte V, Zanovello P, Krampera M, Mosna F, Cestari T, Riviera AP, Brutti N, Barbieri O, Matera L, Tridente G, Colombatti M, Sartoris S. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. *Vaccine*. 2010 Apr 30;28(20):3548-57. doi:10.1016/j.vaccine.2010.03.007. Epub 2010 Mar 19. PMID: 20304037.
 164. Ruggero K, Corradin A, Zanovello P, Amadori A, Bronte V, Ciminale V, D'Agostino DM. Role of microRNAs in HTLV-1 infection and transformation. *Mol Aspects Med*. 2010 Oct;31(5):367-85. doi:10.1016/j.mam.2010.05.001. Epub 2010 Jun 17. PMID: 20600265.
 165. Marigo I, Bosio E, Solito S, Mesa C, Fernández A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S, Bronte V. Tumor-induced tolerance and immune suppression depend on C/EBPβ transcription factor. *Immunity*. 2010 Jun 25;32(6):790-802. doi:10.1016/j.immuni.2010.05.010. Epub 2010 Jun 3. PMID: 20605485.
 166. Grohmann U, Bronte V. Control of immune response by amino acid metabolism. *Immunol Rev*. 2010 Jul;236:243-64. doi:10.1111/j.1600-065X.2010.00915.x. PMID: 20636821.

167. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition. *Curr Opin Immunol.* 2010 Apr;22(2):238-44. doi:10.1016/j.coi.2010.01.021. Epub 2010 Feb 17. PMID: 20171075.
168. Ugel S, Scarselli E, Iezzi M, Mennuni C, Pannellini T, Calvaruso F, Cipriani B, De Palma R, Ricci-Vitiani L, Peranzoni E, Musiani P, Zanovello P, Bronte V. Autoimmune B cell lymphopenia following successful adoptive therapy with telomerase-specific T lymphocytes. *Blood.* 2010 Feb 18;115(7):1374-84. doi:10.1182/blood-2009-07-233270. Epub 2009 Nov 10. PMID: 19903903.
169. Comment in: Targeting telomerase: T-cell friendly fire. Calado RT. *Blood.* 2010 Feb 18;115(7):1316. doi: 10.1182/blood-2009-12-254961. PMID: 20167708.
170. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F, Bronte V. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subset is determined by GM-CSF. *Frontline paper. Eur J Immunol.* 2010 Jan;40(1):22-35. doi:10.1002/eji.200939903. PMID: 19941314.
171. Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Schneck JP, Oelke M, Bronte V. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. *Cancer Res.* 2009 Dec 15;69(24):9376-84. doi:10.1158/0008-5472.CAN-09-0400. PMID: 19934317.
172. Bronte V. Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. *Eur J Immunol.* 2009 Oct; 39(10):2670-2 doi: 10.1002/eji.200939892. PMID: 19757440.
173. Comment in: Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Greifengberg V, Ribechini E, Rössner S, Lutz MB. *Eur J Immunol.* 2009 Oct;39(10):2865-76. doi: 10.1002/eji.200939486. PMID: 19637228.
174. Ugel S, Delpozzo F, Desantis G, Papalini F, Simonato F, Sonda N, Zilio S, Bronte V. Therapeutic targeting of myeloid-derived suppressor cells. *Curr Opin Pharmacol.* 2009 Aug;9(4):470-81 doi:10.1016/j.coph.2009.06.014. Epub 2009 Jul 16. PMID: 19616475.
175. Persano L, Moserle L, Esposito G, Bronte V, Barbieri V, Lafrate M, Gardiman MP, Larghero P, Pfeffer U, Naschberger E, Stürzl M, Indraccolo S, Amadori A. Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. *Carcinogenesis.* 2009 May;30(5):851-60. doi:10.1093/carcin7b9p052. Epub 2009 Feb 23. PMID: 19237608.
176. Bronte V, Mocellin S. Suppressive influences in the immune response to cancer. *J Immunother.* 2009 Jan;32(1):1-11. doi:10.1097/CJI.0b013e3181837276. PMID: 19307988.
177. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V, Zanovello P. IL4Ralpha+myeloid-derived suppressor cell expansion in cancer patients. *J Immunol.* 2009 May 15;182(10):6562-8. doi:10.4049/jimmunol.0803831. PMID: 19414811.
178. Tosello V, Zamarchi R, Merlo A, Gorza M, Piovan E, Mandruzzato S, Bronte V, Wang X, Ferrone S, Amadori A, Zanovello P. Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. *Eur J Immunol.* 2009 Jan;39(1):56-66. doi:10.1002/eji.200738098. PMID: 19065646.
179. Mennuni C, Ugel S, Mori F, Cipriani B, Iezzi M, Pannellini M, Lazzaro D, Ciliberto G, La Monica N, Zanovello P, Bronte V, Scarselli E. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induce mouse models of cancer. *Cancer Res.* 2008 Dec 1;68(23):9865-74. doi:10.1158/0008-5472.CAN-08-1603. PMID: 19047176.
180. Bronte V. Th17 and cancer: friends or foes? *Blood.* 2008 Jul 15;112(2):214. doi:10.1182/blood-2008-04-149260. PMID: 18606882.
181. Comment in: Tumor-specific Th17-polarized cells eradicate large established melanoma. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP. *Blood.* 2008 Jul 15;112(2):362-73. doi: 10.1182/blood-2007-11-120998. Epub 2008 Mar 19. PMID: 18354038.
182. Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, Bronte V. Myeloid-derived suppressor cell role in tumor-related inflammation. *Cancer Lett.* 2008 Aug 28;267(2):216-25 doi:10.1016/j.canlet.2008.03.012 Epub 2008 Apr 22. PMID: 18433992.
183. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid-derived suppressor cells. *Immunol Rev.* 2008 Apr;222:162-79. doi:10.1111/j.1600-065X.2008.00602.x. PMID: 18364001.
184. Peranzoni E, Marigo I, Dolcetti L, Ugel S, Sonda N, Taschin E, Mantelli B, Bronte V, Zanovello P. Role of arginine metabolism in immunity and immunopathology. *Immunobiology.* 2007;212(9-10):795-812. doi:10.1016/j.imbio.2007.09.008. Epub 2007 Nov 14. PMID: 18086380.
185. Viola A, Bronte V. Metabolic mechanisms of cancer-induced inhibition of immune responses. *Semin Cancer Biol.* 2017 Aug;17(4):309-16. doi:10.1016/j.semcancer.2007.06.005. Epub 2007 Jun23. PMID: 17651958.
186. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunctions during tumor development. *J Clin Invest.* 2007 May;117(5):1155-6. doi:10.1172/JCI31422. PMID: 17476345.
187. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenber S, Schreiber H. The terminology issue for myeloid-derived suppressor cells. *Cancer Res.* 2007 Jan 1;67(1):425; author reply 426. doi:10.1158/0008-5472.CAN-06-3037. PMID: 17210725.
188. Comment in: Re: The terminology issue for myeloid-derived suppressor cells.

189. Kristal G, Sly L, Antignano F, Ho V, Ruschmann J, Hamilton M. Cancer Res. 2007 Apr 15;67(8):3986. doi: 10.1158/0008-5472.CAN-07-0211. PMID: 16818658.
190. Mocellin S, Bronte V, Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev. 2007 May;27(3):317-52. doi:10.1002/med.20092. PMID: 16991100.
191. Serafini P, Meckel K, Kelso M, Noonan KA, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006 Nov 27;203(12):2691-702. doi:10.1084/jem.0061104. Epub 2006 Nov 13. PMID: 17101732.
192. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Biciato S, Bronte V. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006 Oct;116(10):2777-90. doi:10.1172/JCI28828. PMID: 17016559.
193. Comment in: Myeloid suppressor cells regulate the adaptive immune response to cancer. Frey AB. J Clin Invest. 2006 Oct;116(10):2587-90. doi: 10.1172/JCI29906. PMID: 17016554.
194. Bronte V, Cingarlini S, Marigo I, De Santo C, Gallina G, Dolcetti L, Ugel S, Peranzoni E, Mandruzzato S, Zanovello P. Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. Immunol Invest. 2006;35(3-4):327-57. doi:10.1080/08820130600754994. PMID: 16916757.
195. Orabona C, Puccetti P, Vacca C, Biciato S, Luchini A, Fallarino F, Bianchi R, Perruccio K, Velardi A, Bronte V, Fioretti MC, Grohmann U. Towards the identification of a tolerogenic signature in IDO-competent dendritic cells. DAP12 and IRF-8 regulate tryptophan catabolism. Blood. 2006 Apr 1;107(7):2846-54. doi:10.1182/blood-2005-10-4077. Epub 2005 Dec 8. PMID: 16339401.
196. Biswas Sk, Gangi L, Paul S, Schioppa T, Sacconi A, Sironi M, Bottazzi B, Doni A, Bronte V, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A. A distinct and unique transcriptional program expressed by tumor-associated macrophages: defective NF- κ B and enhanced IRF-3/STAT1 activation. Blood. 2006 Mar 1;107(5):2112-22. doi:10.1182/blood-2005-01-0428. Epub 2005 Nov 3. PMID: 16269622.
197. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol. 2006 Feb;16(1):53-65. doi:10.1016/j.semcancer.2005.07.005. Epub 2005 Sep 15. PMID: 16168663.
198. Mocellin S, Mandruzzato S, Zanovello P, Bronte V. Cancer rejection by the immune system: forcing the check-points of tumor immune escape. Drug Discovery Today: disease mechanisms; 2:191-197, 2005. doi:10.1016/j.ddmec.2005.05.016
199. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005 Aug;5(8):641-54. doi:10.1038/nri1668. PMID: 16056256.
200. Avogadri F, Martinoli C, Petrovska L, Chiodoni C, Transidico P, Bronte V, Colombo MP, Dougan G, Rescigno M. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res. 2005 May 1;65(9):3920-7. doi:10.1158/0008-5472.CAN-04-3002. PMID: 15867392.
201. Bronte V, Kasic T, Gri G, Gallana K Borsellino G, Marigo I, Battistini L, Iafate M, Prayer-Galetti T, Pagano F, Viola A. Boosting anti-tumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005 Apr 18;201(8):1257-68. doi:10.1084/jem.20042028. Epub 2005 Apr 11. PMID: 15824085.
202. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, Melani C, Guiducci C, Colombo MP, Iezzi M, Musiani P, Zanovello P, Bronte V. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4185-90. doi:10.1073/pnas.0409783102. Epub 2005 Mar 7. PMID: 15753302.
203. Mocellin S, Mandruzzato S, Bronte V, Marincola F. Cancer Vaccines: pessimism in check. Nat Med. 2004 Dec;10(12):1278-9; author reply 1279-80. doi:10.1038/nm1204-1278. PMID: 15580242.
204. Comment in: Cancer immunotherapy: moving beyond current vaccines.
205. Rosenberg SA, Yang JC, Restifo NP. Nat Med. 2004 Sep;10(9):909-15. doi: 10.1038/nm1100. PMID: 15340416.
206. Mocellin S, Mandruzzato S Bronte V, Lise M, Nitti D. Part 1: vaccines for solid tumors. Lancet Oncol. 2004 Nov;5(11):681-9. doi:10.1016/S1470-2045(04)01610-9. PMID: 15522656.
207. Comment in: Use of standard criteria for assessment of cancer vaccines.
208. Restifo NP, Rosenberg SA. Lancet Oncol. 2005 Jan;6(1):3-4. doi: 10.1016/S1470-2045(04)01693-6. PMID: 15629270.
209. De Palma R, Marigo I, Del Galdo F, De Santo c, Serafini P, Cingarlini S, Tüting T, Lenz J, Basso G, Zanovello P, Bronte V. Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent TCR- α usage by melanoma-specific CD8+ T lymphocytes. Cancer Res. 2004 Nov 1;64(21):8086-76. doi:10.1158/0008-5472.CAN-04-0067. PMID: 15520218.
210. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune system through the recruitment of myeloid suppressor cells. Cancer Res. 2004 Sep 1;64(17):6337-43. doi:10.1158/0008-5472.CAN-04-0757. PMID: 15342423.
211. Sfondrini L, Besusso D, Bronte V, Macino B, Rossini A, Colombo MP, Menard S, Balsari A. CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response. Cancer Immunother. 2004 Aug;53(8):697-704. doi:10.1007/s00262--004-0516-x. Epub 2004 Mar 18. PMID: 15034674.
212. Bronte V, Cingarlini S, Apolloni E, Sefaini P, Marigo I, De Santo C, Macino B, Marin O, Zanovello P. Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. J Immunol. 2003 Dec 15;171(12):6396-405. doi:10.4049/jimmunol.171.12.6396. PMID: 14662838.
213. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V. Derangement of immune

- responses by myeloid suppressor cells. *Cancer immunol immunother*. 2004 Feb;53(2):64-75. doi:10.1007/s00262-003-0443-2 Epub 2003 Oct 30. PMID: 14593498.
214. Cozzi E, Cadrobbi R, Baldan N, Dedja A, Calabrese F, Castagnaro M, Fante F, Iacopetti I, Ravarotto L, Carraro P, Bronte V, De Santo C, Busetto R, Plebani M, Cancellotti FM, Rigotti P, Thiene G, Ancona E. Methotrexate for immunosuppression in life-supporting pig-to-cynomolgus monkey renal xenotransplantation. *Xenotransplantation*. 2003 Nov;10(6):287-95. doi:10.1034/j.1399-3089.2003.00060.x. PMID: 14708527.
 215. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T lymphocyte functions. *Trends Immunol*. 2003 Jun;24(6):302-6. doi:10.1016/s1471-4906(03)00132-7. PMID: 12810105.
 216. Bronte V, Serafini P, Marigo I, De Santo C, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, Colombo MP, Zanovello P. IL-4 induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. *J Immunol*. 2003 Jan 1; 170(1):270-8 doi:10.4049/jimmunol.170.1.270. PMID: 12496409.
 217. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM. Myeloid suppressor lines inhibit T cell responses by a nitric oxide dependent mechanism. *J Immunol*. 2002 Jan 15;168(2):689-95. doi:10.4049/jimmunol.168.2.689. PMID: 11777962.
 218. Milan G, Apolloni A, Bronte V, Dalla Santa S, Macino B, Mandruzzato S, Rosato A, Quinteri L, Serafini P, Zoso A, Zanovello P. Antitumor DNA vaccines. *J Immunol. Immunopharmacol.*, 21:86-93, 2001.
 219. Bronte V, Serafini P, Apolloni E, Zanovello P. Tumor-induced dysfunctions caused by myeloid suppressor cells. *J Immunother*. 2001 Nov-Dec;24(6):431-46. doi:10.1097/00002371-200111000-00001. PMID: 11759067.
 220. Bronte V. Genetic vaccination for the active immunotherapy of cancer. *Curr Gene Ther*. 2001 May;1(1):53-100. doi:10.2174/1566523013348931. PMID: 12109138.
 221. Mendiratta KS, Thai G, Eslahi NK, Thull N, Matar M, Bronte V, Pericle F. Therapeutic tumor immunity induced by pole-immunization with melanoma antigens gp100 and TRP-2. *Cancer Res*. 2001 Feb 1;61(3):859-63. PMID: 11221870.
 222. Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondinelli D, Zanon P, Tura S. Antitumor vaccination: where we stand. *Haematologica*. 2000 Nov;85(11):1172-206. PMID: 11074658.
 223. Apolloni E, Bronte V, Mazzoni A, Serafini P, Cabrelle A, Segal DM, Young HO, Zanovello P. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. *J Immunol*. 2000 Dec 15;165(12):6723-30. doi:10.4049/jimmunol.165.12.6723. PMID: 11120790.
 224. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zanovello P, Restifo NP, Zanovello P. Identification of a CD11b+/Gr-1/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. *Blood*. 2000 Dec 1;96(12):3838-46. PMID: 11090068.
 225. Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Restifo NP, Zanovello P. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. *Cancer Res*. 2000 Jan 15;60:253-8. PMID: 10667570.
 226. Lollini PL, Bronte V. The immunotherapy of cancer: understanding the mechanisms through animal models. *Minerva Biotechn.*, 11:283-294, 1999.
 227. Kaufman HL, Rao JB, Irvine KR, Bronte V, Rosenberg SA, Restifo NP. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. *J Immunother*. 1999 Nov;22(6):489-96. doi:10.1097/00002371-199911000-00003. PMID: 10570747.
 228. Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP. Unopposed production of GM-CSF by tumors inhibits CD8+ T cell responses by dysregulating antigen presenting cell maturation. *J Immunol*. 1999 May 15;162(10):5728-37. PMID: 10229805.
 229. Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, Restifo NP. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. *J Immunol*. 1998 Nov 15; 161(10):5313-20. PMID: 9820504.
 230. Pericle F, Kirken RA, Bronte V, Sconocchia G, DaSilva L, Segal DM. Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. *J Immunol*. 1997 Sep 15;159(6):2580-5. PMID: 9300676.
 231. Bronte V, Carroll MW, Goletz TJ, Wang W, Overwijk WW, Marincola F, Rosenberg SA, Moss B, Restifo NP. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. *Proc Natl Acad Sci U S A*. 1997 Apr 1;94(7):3183-8. doi:10.1073/pnas.94.7.3183. PMID: 9096367.
 232. Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. *Cancer res*. 1996 Jun 15; 56(12):2832-6. PMID: 8665522.
 233. Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine K, Moss B, Rosenberg SA, Restifo NP. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. *J Immunol*. 1996 May 1;156(9):3357-65. PMID: 8617961.
 234. Bronte V, Macino B, Zamboni A, Rosato A, Mandruzzato S, Zanovello P, Collavo D. Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5'-triphosphate. *Biochem Biophys Res Commun*. 1996 Jan 5;218(1):344-51. doi:10.1006/bbrc.1996.0060. PMID: 8573158.
 235. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. *J Immunol*. 1996 Jan 1; 156(1):224-31. PMID: 8598466.
 236. Rosato A, Zamboni A, Macino B, Mandruzzato S, Bronte V, Milan G, Zanovello P, Collavo D. Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining

- the tumor area. *Int J Cancer*. 1996 Mar 15;65(6):847-51. doi:10.1002(SICI)1097-0215(19960315)65:6<847:AID-IJC23>3.0.CO;2-#. PMID: 8631602.
237. Bronte V. Molecular genetics of cancer. Gene therapy and other novel therapeutic approaches. *Cancer*. 1995 Nov 15; 76(10):1878-81. doi: 10.1002/1097-0142(19951115)76:10<1878:aid-cnrcr2820761032>3.0.co;2-7. PMID: 8625063.
 238. Rosato A, Mandruzzato S, Bronte V, Zambon A, Macino B, Calderazzo F, Zanovello P, Collavo D. Role of anti-LFA-1 and anti-ICAM-1 combined Mab treatment in the rejection of tumors induced by Moloney murine sarcoma virus (M-MSV). *Int J Cancer*. 1995 May 4;61(3):355-62. doi:10.1002/ijc.2910610314. PMID: 7729948.
 239. Di Virgilio F, Zanovello P, Zambon A, Bronte V, Pizzo P, Murgia M. Cell membrane receptors for extracellular ATP: a new family of apoptosis-signalling molecules. *Fund Clin Immunol*. 1995; 3:80-81.
 240. Wang M, Chen PW, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor antigen. *J Immunother Emphasis Tumor Immunol*. 1995 Oct;18(3):139-46 doi:10.1097/00002371-199510000-00001. PMID: 8770769.
 241. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. *J Immunol*. 1995 May 15;154(10):5282-92. PMID: 7730632.
 242. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP. Active Immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. *J Immunol*. 1995 May 15;154(9):4685-92. PMID: 7722321.
 243. Rosato A, Zambon A, Mandruzzato S, Bronte V, Macino B, Calderazzo F, Collavo D, Zanovello P. Inhibition of protein tyrosine phosphorylation prevents T-cell mediated cytotoxicity. *Cell Immunol*. 1994 Dec;159(2):294-305. doi:10.1006/cimm.1994.1315. PMID: 7994761.
 244. Zambon A, Bronte V, Di Virgilio F, Hanau S, Steinberg TH, Collavo D, Zanovello P. Role of extracellular ATP in cell-mediated cytotoxicity: a study with ATP-sensitive and ATP-resistant macrophages. *Cell Immunol*. 1994 Jul;156(2):458-67. doi:10.1006/cimm.1994.1190. PMID: 8025958.
 245. Mandruzzato S, Rosato A, Bronte V, Zanovello P, Amboldi N, Ballinari D, Collavo D. Adoptive transfer of lymphokine-activated killer cells loaded with 4'-deoxy-4'-iododoxorubicin: therapeutic effect in mice bearing lung metastases. *Cancer Res*. 1994 Feb 15;54(4):1016-20. PMID: 8313356.
 246. Bronte V, Zanovello P, Rosato A, Zambon A, Mandruzzato S, Pizzo P, Di Virgilio F, Collavo D. Synergistic effect of extracellular adenosine 5' - triphosphate and tumor necrosis factor on DNA degradation. *Cell Immunol*. 1993 Nov; 152(1):110-9. doi: 10.1006/cimm.1993.1271. PMID: 8242754.
 247. Rosato A, Bronte V, Mandruzzato S, Zambon A, Calderazzo F, Biasi G, Zanovello P, Collavo D. Role of adhesion molecules in the immune reaction to M-MSV-induced tumors. *Int J Cancer Suppl*. 1992;7:24. PMID: 1385341.
 248. Mandruzzato S, Rosato A, Bronte V, Pollis F, Zambon A, Zanovello P, Collavo D. Therapeutical effect of 4'-deoxy-4'-iododoxorubicin-loaded LAK cells in mice bearing lung metastases. *Pharmacol Res*. 1992 Sep;26 Suppl 2:124-5. doi:10.1016/1043-6618(92)90628-o. PMID: 1409274.
 249. Pollis F, Bronte V, Mandruzzato S, Rosato A, Zambon A, Zanovello P, Zambello R, Callegaro L, Collavo D. Inhibition of CTL-line lysis after gangliosides treatment. *Pharmacol Res*. 1992 Sep; 26 Suppl 2:190-1. doi:10.1016/1043-6618(92)90659-y. PMID: 1409305.
 250. Pollis F, Rosato A, Bronte V, Mandruzzato S, Zambon A, Zambello R, Pizzo P, Zanovello P. Interaction of large granular lymphocytes with susceptible target does not induce second messenger and cytolytic granule exocytosis. *Leukemia*. 1992; 6 Suppl 3:92S-93S. PMID: 1602835.
 251. Rosato A, Bronte V, Pollis F, Mandruzzato S, Zambon A, Zanovello P, Collavo D. The in vivo role of leukocyte function-associated antigen-1 (LFA-1) in cytotoxic cell activity against tumors induced by the retroviral complex M-MSV/M-MuLV. *Leukemia*. 1992; 6 Suppl 3:166S-167S. PMID: 1602816.
 252. Zanovello P, Rosato A, Bronte V, Mandruzzato S, Cerundolo V, Collavo D. Anti-tumor efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. *Cancer Immunol Immunother*. 1992;35(1):27-32. doi:10.1007/BF01741051. PMID: 1611620.
 253. Pizzo P, Murgia M, Zambon A, Zanovello P, Bronte V, Di Virgilio F. Role of P2z purinergic receptors in ATP-mediated killing of TNF-sensitive and TNF-resistant L929 fibroblasts. *J Immunol*. 1992 Nov 15;149(10):3372-8. PMID: 1431111.
 254. Pizzo P, Zanovello P, Bronte V, Di Virgilio F. Extracellular ATP causes lysis of mouse thymocytes and activates a plasma membrane ion channel. *Biochem J*. 1991 Feb 15;274(Pt 1)(Pt1):139-44. doi:10.1042/bj2740139. PMID: 1705798.
 255. Zanovello P, Vallerani E, Bronte V, Rosato A, Chieco-Bianchi L, Collavo D. Tolerance induction in adult mice intrathecally injected with moloney murine leukemia virus and treated with cyclophosphamide. *J Immunol. Research*. 2:151-156, 1990.
 256. Zanovello P, Bronte V, Rosato A, Pizzo P, Di Virgilio F. Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. *J Immunol*. 1990 Sep 1;145(5):1545-50. PMID: 2384670.
 257. Di Virgilio F, Pizzo P, Zanovello P, Bronte V, Collavo D. Extracellular ATP as a possible mediator of cytotoxicity. *Immunol Today*. 1990 Aug;11(8):247-7. doi:10.1016/0167-5699(90)90111-I. PMID: 2206271.
 258. Di Virgilio F, Bronte V, Collavo D, Zanovello P. Responses of mouse lymphocytes to extracellular adenosine 5' - triphosphate (ATP). *J Immunol*. 1989 Sep 15; 143(6):1955-60. PMID: 2789252.
 259. Zanovello P, Cerundolo V, Bronte V, Giunta M, Panozzo M, Biasi G, Collavo D. Resistance of lymphokine-activated T lymphocytes to cell-mediated cytotoxicity. *Cell Immunol*. 1989 Sep;122(2):450-60. doi:10.1016/0008-8749(89)90091-9. PMID: 2788517.

260. Zanolello P, Rosato A, Bronte V, Cerundolo V, Treves S, Di Virgilio F, Pozzan T, Biasi G, Collavo D. Interaction of lymphokine-activate killer cells with susceptible targets does not induce second messenger generation and cytolytic granule exocytosis. *J Exp Med*. 1989 Sep 1;170(3):665-77. doi:10.1084/jem.170.3.665. PMID: 2769181.